Table 6.
Patients’ characteristics and levels of CMTM1_v17 expression in patients received NAC (n = 78)
| Variable | CMTM1_v17 expression no. (%) | P value | |
|---|---|---|---|
| High | Low | ||
| Age | 0.315 | ||
| ≤ 55 | 13(40.6) | 19(59.4) | |
| > 55 | 22(47.8) | 24(52.2) | |
| Gender | 0.308 | ||
| Male | 27(42.2) | 37(57.8) | |
| Female | 8(57.1) | 6(42.9) | |
| Smoking history | 0.593 | ||
| Non-smoker | 10(50.0) | 10(50.0) | |
| Smoker | 25(43.1) | 33(56.9) | |
| Histology | 0.352 | ||
| Adenocarcinoma | 13(43.3) | 17(56.7) | |
| Non-adenocarcinoma | 22(45.8) | 26(54.2) | |
| Histologic grading | 0.465 | ||
| Poorly | 15(40.5) | 22(59.5) | |
| Moderate and well | 20(48.8) | 21(51.2) | |
| Venous invasion | 0.506 | ||
| Negative | 29(46.8) | 33(53.2) | |
| Positive | 6(37.5) | 10(62.5) | |
| Pathological stage | 0.856 | ||
| I/II | 18(43.9) | 23(56.1) | |
| III | 17(45.9) | 20(54.1) | |
P value was calculated using Pearson’s χ2 test.
NAC neoadjuvant chemotherapy